Literature DB >> 3220888

Isolation of basic drugs from plasma using solid-phase extraction with a cyanopropyl-bonded phase.

G Musch1, D L Massart.   

Abstract

The use of a CN sorbent for the isolation of basic compounds from plasma is described. Adsorption from water and plasma was investigated for a test set of 30 basic drugs. It was found that compounds with a carbon chain length greater than or equal to 11 are totally retained and that the competitive effect of the matrix on the adsorption is minimal. Methanol-phosphate buffer (pH 3, mu = 0.05) (50:50) yielded good recoveries for more polar compounds; apolar basic drugs can be efficiently eluted using methanol containing 0.1% propylamine. Water up to 3 ml can be used for the washing step. This approach was applied to the determination of eight drugs in plasma at therapeutic levels. The absolute recoveries (n = 6) obtained were 98.8 +/- 7.3% for papaverine, 82.3 +/- 3.9% for practolol, 83.4 +/- 2.6% for metoclopramide, 87.3 +/- 5.8% for imipramine, 82.8 +/- 3.3% for procaine, 82.7 +/- 4.6% for morphine, 87.5 +/- 7.2% for propranolol and 90.4 +/- 6.2% for yohimbine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3220888     DOI: 10.1016/s0378-4347(00)80646-5

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Nicardipine does not influence the pharmacokinetics and pharmacodynamics of atenolol.

Authors:  I Vercruysse; D F Schoors; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

2.  Evaluation of a solid-phase extraction procedure for the simultaneous determination of morphine, 6-monoacetylmorphine, codeine and dihydrocodeine in plasma and whole blood by GC/MS.

Authors:  A Geier; D Bergemann; L von Meyer
Journal:  Int J Legal Med       Date:  1996       Impact factor: 2.686

3.  Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.

Authors:  D F Schoors; I Vercruysse; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.